Literature DB >> 24413081

Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.

C Xu1, C D Fan1, X Wang1.   

Abstract

Mdm2 is a critical negative regulator of the tumor suppressor protein p53. Mdm2 is an E3 ligase whose overexpression leads to functional inactivation of p53. Mdm2 protein stability is regulated by several mechanisms including RING (Really Interesting New Gene) domain-mediated autoubiquitination. Here we report biochemical identification of NEDD4-1 as an E3 ligase for Mdm2 that contributes to the regulation of Mdm2 protein stability in cells. NEDD4-1 was identified from Jurkat cytosolic fractions using an enzyme-dead Mdm2 mutant protein as a substrate for in vitro E3 ligase assays. We show that lysates from Nedd4-1 knockout (KO) mouse embryonic fibroblasts (MEFs) have significantly diminished E3 ligase activity toward Mdm2 compared with lysates from wild-type (WT) MEFs. Recombinant NEDD4-1 promotes Mdm2 ubiquitination in vitro in a concentration- and time-dependent manner. In cells, NEDD4-1 physically interacts with Mdm2 via the RING domain of Mdm2. Overexpression of NEDD4-1, but not an enzyme-dead NEDD4-1CS mutant, increases ubiquitination of Mdm2. NEDD4-1 catalyzes the formation of K63-type polyubiquitin chains on Mdm2 that are distinct from K48-type polyubiquitination chains mediated by the Mdm2/MdmX complex. Importantly, K63-type polyubiquitination by NEDD4-1 competes with K48-type polyubiquitination on Mdm2 in cells. As a result, NEDD4-1-mediated ubiquitination stabilizes Mdm2. NEDD4-1 knockdown reduces the t1/2 (half-life) of endogenous Mdm2 from 20 to 12 min in U2OS cells. Nedd4-1 KO MEFs manifest increased p53 levels and activity, a more robust DNA damage response and increased G1 arrest compared with WT MEFs. Similarly, NEDD4-1 knockdown in WT-p53-bearing cells increases basal p53 levels and activity in an Mdm2-dependent manner, causes stronger p53 responses to DNA damage and results in p53-dependent growth inhibition compared with corresponding NEDD4-1-proficient control cells. This study identifies NEDD4-1 as a novel component of the p53/Mdm2 regulatory feedback loop that controls p53 activity during stress responses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24413081     DOI: 10.1038/onc.2013.557

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization.

Authors:  Z Lai; K V Ferry; M A Diamond; K E Wee; Y B Kim; J Ma; T Yang; P A Benfield; R A Copeland; K R Auger
Journal:  J Biol Chem       Date:  2001-06-07       Impact factor: 5.157

Review 2.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

3.  Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis.

Authors:  Qing Zhong; Wenhua Gao; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

4.  Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.

Authors:  K Linke; P D Mace; C A Smith; D L Vaux; J Silke; C L Day
Journal:  Cell Death Differ       Date:  2008-01-25       Impact factor: 15.828

5.  MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.

Authors:  Xinjiang Wang; Junru Wang; Xuejun Jiang
Journal:  J Biol Chem       Date:  2011-05-13       Impact factor: 5.157

6.  NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway.

Authors:  Peter W Eide; Lina Cekaite; Stine A Danielsen; Ina A Eilertsen; Ane Kjenseth; Tone A Fykerud; Trude H Ågesen; Jarle Bruun; Edgar Rivedal; Ragnhild A Lothe; Edward Leithe
Journal:  Cell Signal       Date:  2012-09-05       Impact factor: 4.315

7.  MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation.

Authors:  Jer-Yen Yang; Cong S Zong; Weiya Xia; Yongkun Wei; Mohamed Ali-Seyed; Zheng Li; Kristine Broglio; Donald A Berry; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

8.  Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.

Authors:  Hiroyuki Inuzuka; Alan Tseng; Daming Gao; Bo Zhai; Qing Zhang; Shavali Shaik; Lixin Wan; Xiaolu L Ang; Caroline Mock; Haoqiang Yin; Jayne M Stommel; Steven Gygi; Galit Lahav; John Asara; Zhi-Xiong Jim Xiao; William G Kaelin; J Wade Harper; Wenyi Wei
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

9.  Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.

Authors:  M Zhou; A M Yeager; S D Smith; H W Findley
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

10.  Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling.

Authors:  Yaron Mosesson; David Chetrit; Leehee Schley; Janina Berghoff; Tamar Ziv; Silvia Carvalho; Fernanda Milanezi; Arie Admon; Fernando Schmitt; Marcelo Ehrlich; Yosef Yarden
Journal:  Dev Cell       Date:  2009-05       Impact factor: 12.270

View more
  31 in total

1.  NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors:  Shaoyan Feng; Guangwei Yang; Haidi Yang; Zibin Liang; Rongkai Zhang; Yunping Fan; Gehua Zhang
Journal:  Cell Cycle       Date:  2017-04-05       Impact factor: 4.534

2.  Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.

Authors:  Kailiang Zhao; Yang Yang; Guang Zhang; Chenfeng Wang; Decai Wang; Mian Wu; Yide Mei
Journal:  EMBO Rep       Date:  2018-01-02       Impact factor: 8.807

3.  Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Authors:  Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 4.  NEDD4: The founding member of a family of ubiquitin-protein ligases.

Authors:  Natasha Anne Boase; Sharad Kumar
Journal:  Gene       Date:  2014-12-17       Impact factor: 3.688

5.  Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells.

Authors:  Wu Wen; Jingying Li; Longwang Wang; Yifei Xing; Xuechao Li; Hailong Ruan; Xiaoqing Xi; Jianhua Xiong; Renrui Kuang
Journal:  Cell Cycle       Date:  2017-07-26       Impact factor: 4.534

Review 6.  Regulation of MDM2 Stability After DNA Damage.

Authors:  Jiaqi Li; Manabu Kurokawa
Journal:  J Cell Physiol       Date:  2015-10       Impact factor: 6.384

Review 7.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

8.  The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2.

Authors:  Yizhou He; Laura Tollini; Tae-Hyung Kim; Yoko Itahana; Yanping Zhang
Journal:  Cell Cycle       Date:  2014-05-07       Impact factor: 4.534

Review 9.  NEDD4: a promising target for cancer therapy.

Authors:  Xiantao Ye; Lixia Wang; Bingxue Shang; Zhiwei Wang; Wenyi Wei
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

10.  Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy.

Authors:  Y-C Wang; S-A Wang; P-H Chen; T-I Hsu; W-B Yang; Y-P Chuang; W-C Su; H-J Liaw; W-C Chang; J-J Hung
Journal:  Oncogene       Date:  2015-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.